Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Common Stock (NQ:BIAF)

9.750 +3.160 (+47.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bioAffinity Technologies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
What's going on in today's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednesday's regular session. The company's market cap stands at $3.9 million. Gelteq (NASDAQ:GELS) shares... 
Via Benzinga
Here are the top movers in Wednesday's session. ↗
Via Chartmill
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Catalysts Emerge BIAF, LIDR, SSM, GMGMF to Watch Now
Via AB Newswire
Topics Artificial Intelligence
Here are the top movers in Tuesday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regular session. The company's market cap stands at $2.7 million. USBC (AMEX:USBC) stock moved upwards by... 
Via Benzinga
What's going on in today's session ↗
Via Chartmill
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. Lakewood-Amedex... 
Via Benzinga
News headline image
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
These stocks are the most active in today's session ↗
Via Chartmill
News headline image
Algorhythm Holdings (NASDAQ: RIME) Volume Surges as Q2 Revenue Jumps 161%, Potential Oversold Setup Emerges
Via AB Newswire
Topics Artificial Intelligence
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Q2 Virtual Investor Summit Presentations Now Available On Demand
From Investor Summit Group
Via ACCESS Newswire
News headline image
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Closing of $3.2 Million Offering
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Pricing of $3.2 Million Offering
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
From bioAffinity Technologies, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.